In this randomized prospective study, we included 30 patients with different hematological diseases (acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, myelodysplastic syndrome or severe aplastic anemia) to compare peripheral blood stem cells (PBSC) (15 patients; mean age 23) and bone marrow (BM) (15 patients; mean age 21.8) as a source for allogeneic transplantation regarding the tempo of hematopoietic recovery and the incidence of acute graftversus-host disease (GVHD). In the BM group, the median nucleated cell count harvested was 1.3 ؋ 10 10 , while in the PBSC group, the aphereses contained a median of 4.4 ؋ 10 6 CD34 + /kg recipient weight. PBSC transplantation (PBSCT) was associated with faster hematopoietic reconstitution measured as absolute neutrophil count (ANC) Ͼ0.5 ؋ 10 9 /l (log-rank P value Ͻ0.0018) and platelet count Ͼ25 ؋ 10 9 /l (log-rank P value Ͻ0.0098). Seven patients (46.7%) in the BM group vs only one patient (6.7%) in the PBSC group developed acute GVHD (P ‫؍‬ 0.013). Therefore, we conclude that PBSCT is associated with faster hematopoietic recovery and the incidence of acute GVHD does not exceed that seen with BMT.
In the 1970s, stem cells with engraftment potential were detected in the blood of some animals and of patients with chronic myeloid leukemia. 1, 2 Such stem cells were found also, by the early 1980s, in the blood of other patients, for example, those with leukemia or lymphoma in remission, and during the period of hematopoietic recovery following high-dose chemotherapy. [3] [4] [5] Currently, autologous transplantation using peripheral blood stem cells (PBSCs) is a well established method to reconstitute hematopoiesis following myeloablative therapy. 5, 6 To a much lesser extent, allogeneic PBSCs have been used as the sole support for hematopoietic reconstitution after myeloablative treatment because of concerns about durability of engraftment and risk of graft-versus-host disease (GVHD). 7, 8 In this randomized study, we evaluated the difference between PBSCs
Patients and methods
In the period between January 1995 and March 1997, 30 patients undergoing allogeneic stem cell transplantation (BMT Unit, NCI, Cairo University) were randomized to receive either BM (15 patients) or PBSC (15 patients) following myeloablative therapy. As shown in Table 1 , patients in the BM group were 12 males and three females, while in the PBSC group, 11 were males and four were females. In both groups, the age ranged from 16 to 42 years with a mean of 21.8 vs 23 (BM vs PBSC, respectively). Table 1 also shows the diagnosis and stage of the disease at the time of transplantation, as well as the type of preparative regimen used. All donors were HLA-identical siblings; in the BM group, the marrow was harvested conventionally in the operating theater under general anasthesia. In the PBSC group, donors were given subcutaneous Filgrastim (Roche, Basel, Switzland) at a daily dose of 10 g/kg. On the fourth day of Filgrastim administration, daily apheresis was performed until the target number of CD34 + cells (Ͼ2.0 × 10 6 /kg recipient weight) was met. The daily growth factor administration was continued until completion of ). The only complaint reported by the PBSC donors was mild bone pain in eight out of the 15 individuals. Otherwise, the procedure was very well tolerated.
Concerning CD34 + cell estimation, monoclonal antibody detecting class III CD34 (HPCA-2 clone PE; Becton Dickinson, San Jose, CA, USA) and the isotype (IgG1 PE; Becton Dickinson) were used. We performed a whole blood staining method, where 100 l of whole blood were incubated with 10 l CD34 monoclonal antibody in one tube and an isotype control in another. After 30 min of incubation, cells were washed twice, once with hemolyzing solution and then with PBS. This was followed by suspension of the cells in 500 l PBS.
Cells were then analyzed for forward and side scatter using a FACS flowcytometer (Becton Dickinson). The gates were defined on the population with low side scatter and CD34
+ events estimated. Total CD34
The value obtained was then divided by the recipient's body weight. All patients had a central venous line and were nursed under strict protective isolation in barrier nursing units with HEPA-filtered air. For the remaining supportive care (including antimicrobial prophylaxis, hydration, hemorrhagic cystitis prophylaxis, parenteral nutrition, and blood component support), all patients were managed using the same protocol. Patients who received the CY-TBI regimen (all but one patient) were given a total dose of radiotherapy of 10 Gy fractionated over 4 consecutive days (4 × 2.5 Gy), followed by cyclophosphamide 60 mg/kg/day for 2 consecutive days. Regarding the BU-CY regimen (received by one patient in the PBSC group), patients were to receive busulfan 4 mg/kg/day for 4 consecutive days followed by cyclophosphamide 60 mg/kg/day for 2 consecutive days. All patients were given growth factor support (GM-CSF 10 g/kg/day) starting from T +1 until neutrophil recovery. Cyclosporine (CSP) + methotrexate (MTX), as GVHD prophylaxis, were given to all patients in both groups. The former was given in an i.v. dose of 3 mg/kg/day until resumption of oral intake, while the latter was given as 15 mg/m 2 on day 1 then 10 mg/m 2 on days 3, 6 and 11 by i.v. route.
Informed consent was obtained from all patients and donors. In all cases, the stem cell harvests (or collections) were infused unmanipulated. In the statistical analysis, distribution of the time-to-event data was estimated using the Kaplan-Meier method (Figures 1-4) . Time-to-event data were analyzed using the log rank test. The significance for all other differences between both groups was estimated with the 2 test.
Results
All patients engrafted promptly except four patients who died early in the post-transplant period. Two of these were in the BM group. One died from severe catheter-related sepsis, while grade IV acute GVHD was the cause of death in the other. The other two patients were in the PBSC group. One of them died as a result of veno-occlusive disease (VOD), while the other died from grade IV acute GVHD. The hematopoietic reconstitution was faster for PBSCT group as shown in the Kaplan-Meier plots ( Figures  1-4) , which demonstrate the tempo of the hematopoietic recovery for both groups as measured by ANC Ͼ0.5 × 10 9 /l (log-rank P value Ͻ0.0018), ANC Ͼ1 × 10 9 /l (log-rank P value Ͻ0.0035), platelet recovery Ͼ25 × 10 9 /l (log-rank P value Ͻ0.0098) and platelet count Ͼ100 × 10 9 /l (log-rank P value Ͻ0.0132). Faster hematopoietic recovery in the PBSC group reflected positively on the duration of both neutropenic fever and hospitalization. In the BM group, the mean number of days with neutropenic fever was 14.9, while it was only 9.8 days in the PBSC group (P = 0.018). As regards the length of hospital stay, it was a mean of 40.9 days in the BM group compared to 25 days in the PBSC group (P = 0.003).
When we evaluated the incidence of acute GVHD in each group, we found that only one patient (6.7%) in the PBSC group developed this complication, compared to seven patients (46.7%) in the BM group (P = 0.013). In the PBSC group, the only patient with this complication died of advanced stage of acute GVHD (stage IV skin, liver and gut). Out of the seven patients in the BM group who developed acute GVHD, one (14.3%) had stage I skin and gut, another one (14.3%) developed stage III skin and liver, while the remaining five patients (71.4%) developed stage IV skin, liver and gut disease.
In the BM group, all the five patients (four AML in first CR) with stage IV acute GVHD, as well as the patient (CML, first CP) with stage III disease died despite aggressive i.v. immunosuppressive therapy. Other causes of death in the BM group included severe catheter-related sepsis (one patient with ALL in second CR) and infectious pneumonitis (one patient with CML in first CP). In the PBSC group, one patient died of VOD; another patient developed severe polymicrobial sepsis, which ended fatally; a third patient died of intracranial hemorrhage, and a fourth died of stage IV acute GVHD. These four patients were transplanted for CML in first CP, ALL in second CR, ALL in second CR, and CML in first CP, respectively.
Discussion
For several years now, autologous transplantation using PBSCs has become almost routine practice in the management of selected patients with leukemia, lymphoma, myeloma, and some solid tumors. 9 Thus, a reasonable question was: are these cells going to work when allografting is considered? In 1993, Russell and colleagues 8 showed the ability of blood-derived progenitors to engraft in the allogeneic setting. In 1995, three reports were published confirming the fact that allografting with these cells does work and can be considered as a realistic, and even very tempting, alternative to BM cells. [10] [11] [12] A total of 25 patients received the blood-derived stem cells from sibling donors and all engrafted promptly and more rapidly than would have been expected with comparable marrow-derived stem cells. At the time of these reports, 20 patients (80%) were alive, one of them for more than 1 year. Those three reports showed that neutrophil and platelet recovery was faster when compared to control patients who received marrow stem cells. Logically speaking, this could translate into less risk of infection and bleeding, reduced blood product support and earlier hospital discharge. In addition, the higher number of T cells in PBSC harvests can reduce the risk of graft failure, especially when there is some degree of HLA disparity. 9 In the current randomized study, our results were in total agreement with the above-mentioned findings, since all patients in both groups engrafted promptly, except those with a fatal course early in the post-transplant period (two patients in each group) mainly because of severe acute GVHD, VOD or catheter-related sepsis. Regarding the tempo of hematopoietic recovery, our results were encour- aging and significantly in favor of PBSCT for both neutrophil and platelet recovery when compared with BMT. This was reflected in the duration of both neutropenic fever and hospital stay, which was also significantly less in the PBSC group. One of the major concerns which argued against the use of PBSCs for allotransplantation is the higher number of T lymphocytes in the PBSC harvest since it greatly exceeds, perhaps by one order of magnitude, the number present in a conventional marrow harvest. [13] [14] [15] Obviously, this raised the possibility of increased incidence and severity of GVHD when PBSCs are used. Probably, this concern can now be dispelled, since many studies showed no evidence that acute GVHD is worse with blood than marrow cells, and in fact it may even be less. [10] [11] [12] In addition, the more recently published data still show no difference in the incidence in the acute GVHD when PBSCT is compared to BMT. 16 Moreover, in the study by Kubel and colleagues 17 it was shown that out of the 12 BMT patients, five developed acute GVHD while 10 out of 24 patients developed this complication in the PBSCT group, a difference which did not reach statistical significance. Thus, the data may sup-port the hypothesis that GVHD severity is based much more on genetic disparities between donor and recipient than on T cell numbers. 9 Also, one may speculate that the higher number of T cells may provide a greater graft-versus-leukemia (GVL) effect. 9 Again, our results agree with the findings regarding the incidence of acute GVHD since only one patient (6.7%) in the PBSC group developed this complication, compared to seven patients (46.7%) in the BM group (P = 0.013). Because our study is a randomized prospective one, the significantly lower incidence of acute GVHD in the PBSC group should be considered as a strongly positive finding since all of our patients were subjected to the same pre-transplant evaluation, received the same regimen of GVHD prophylaxis, and the vast majority of them received the same conditioning regimen.
In conclusion, allogeneic PBSCT proved to be quite feasible and is associated with faster hematopoietic recovery and shorter duration of both neutropenic fever and hospital stay. In addition, the incidence of acute GVHD does not exceed, and may be less than, that seen with BMT. A longer follow-up is definitely needed to determine the ultimate incidence of chronic GVHD in each group.
